Pfizer Ltd. — Board/Management Information 2026

Jan 20, 2026

==> picture [100 x 42] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 20, 2026

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation regarding change in Senior Management Personnel of the Company. Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the below changes in the Senior Management Personnel of the Company:

• (i) Mr. Nilesh Pendse is appointed as Category Lead – Vaccines of the Company with effect from February 1, 2026. Mr. Pendse shall accordingly be a Senior Management Personnel of the Company effective the said date.

• (ii) Mr. Manikantan Seshadrinathan – Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective February 1, 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective January 31, 2026.

• (iii) Mr. Prashant Mahalingam, Category Lead – Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026. The profile and other details of Mr. Mahalingam were already informed to the Stock Exchanges when he was appointed as Category Lead – Internal Medicine, vide our letter dated November 5, 2024.

Additional details required to be disclosed pursuant to the SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of appointment referred to (i) above are enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

Prajee Digitally signed by Prajeet Nair Date: 2026.01.20 t Nair 09:18:54 +05'30'

Prajeet Nair

Director – Corporate Services & Company Secretary

Encl.: A/a

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

Annexure – A

Additional details pursuant to SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123

**Sr.no **	Particulars	Details
1.	Name	Mr. Nilesh Pendse
2.	Reasons for change	Appointment ofMr. Nilesh Pendse as Category Lead – Vaccines
3.	Date of Appointment and Term	February 1, 2026
4.	Affirmation as per List/Comp/14/2018- 19 dated June 20, 2018.	Not Applicable
5.	Relationship inter-se Directors / Key Managerial Personnel / Senior Management Personnel	Mr. Nilesh Pendse is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.
6.	Number of Shares held in the Company	Nil
7.	Brief Profile	Mr. Nilesh Pendse joined Pfizer Products India Private Limited, in 2024, where he led the Oncology Business, focusing on strategic growth, market access, and stakeholder engagement to advance cancer care. Prior to joining Pfizer Products India Private Limited, Mr. Pendse held leadership roles at Boehringer Ingelheim and Novartis where he managed diabetes and neurosciences Divisions, with a focus on sales, marketing, and franchise operations. In addition, Nilesh comes from consulting background experience with firms such as Boston Consulting Group, Ernst & Young (EY) and Accenture, where he led projects related to strategy, revenue acceleration, and business transformation. Mr. Nilesh Pendse holds an MBA in Marketing from Jamnalal Bajaj Institute of Management Studies and a Bachelor’s degree in Electronics Engineering from the University of Mumbai.